Crossmark

SK609, a novel dopamine D3 receptor agonist and norepinephrine transporter blocker with putative pro-cognitive actions, does not induce psychostimulant-like increases in risky choice during probabilistic discounting

Crossref DOI link: https://doi.org/10.1007/s00213-024-06727-1

Published Online: 2024-12-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Knapp, Christopher P.

Fallon, Brooke

Kortagere, Sandhya

Waterhouse, Barry D.

Floresco, Stan B.

Navarra, Rachel L. https://orcid.org/0000-0002-4893-5468
Funding

Funding for this research was provided by:

New Jersey Commission on Brain Injury Research (CBIR20PIL004, CBIR19IRG025)

U.S. Department of Defense (W81XWH-22-1-0616, W81XWH-22-1-0618)

Osteopathic Heritage Foundation (Osteopathic Heritage Foundation)

Rowan University
License Information

Text and Data Mining valid from 2024-12-04

Version of Record valid from 2024-12-04
More Information

Article History

Received: 4 June 2024

Accepted: 25 November 2024

First Online: 4 December 2024

Declarations

:

: On behalf of all authors, the corresponding author states that there are no conflicts of interest.

Document is current

Any future updates will be listed below